CellSave Arabia

الإمارات هي المكان الذي يلتقي فيه الحلم بالواقع! إنها شهادة على الابتكار المستقبلي، بفضل أفقها المرتفع وأحلامها التي لا تعرف حدودًا. في وسط هذا المشهد، تتألق “سيل سيف أرابيا”، بنك خلايا جذعية خاص فريد من نوعه. موجودة في قلب الإمارات، تحتفظ بأهم و أثمن الخلايا، مُقدِّمةً لك الفرصةً للحفاظ على صحة طفلك و عائلتك بأكملها.✨ #cellsavearabia #cellsave #stemcells #cordblood #cordbloodbanking #stemcellbanking #regenerativemedicine #dubai #uae #newborn #baby

A recent Phase 1 study by Wesson et al. (2025) highlights the safety and efficacy of MSCYC-0010, an umbilical cord-derived mesenchymal stromal cell therapy, in patients with high-risk or steroid-refractory acute graft-versus-host disease (aGvHD). The treatment was well-tolerated, with no significant adverse events in 96% of patients. By Day 90, 73% of high-risk patients achieved complete response, demonstrating MSCYC-0010’s potential as a life-saving therapy for this critical condition. These promising results support further trials to advance MSCYC-0010 as a treatment for severe aGvHD. Read more: https://lnkd.in/dt3kyH5C

A recent study by Miram et al. (2025) exploring the effects of human umbilical cord mesenchymal stem cell-derived exosomes (hucMSC-Exos) in a model of multiple sclerosis (MS) shows promising results for improving motor function. The administration of hucMSC-Exos led to enhanced remyelination, reduced demyelination, and improved glial response by modulating microglia and astrocytes. Additionally, hucMSC-Exos upregulated genes associated with the oligodendrocyte lineage, indicating potential for remyelination and recovery. These findings suggest hucMSC-Exos as a novel and effective therapeutic approach for treating demyelinating diseases like MS. Read more:  https://lnkd.in/dyKzvNXW

A recent study by Wang et al. (2025) investigates the therapeutic potential of human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) in improving erectile dysfunction (ED) after cavernous nerve injury (CNI). The findings reveal that varying doses of HUC-MSCs significantly enhanced erectile function, with no significant difference between doses. The treatment increased key markers for endothelial, smooth muscle, and neural cells, promoting tissue regeneration. These results highlight HUC-MSCs as a promising therapy for ED, offering potential for improved tissue health and reduced oxidative stress. Read more: https://lnkd.in/dHcwBf6V

A recent analysis of clinical trials Ishak-Samrin et al. (2025) on Wharton’s jelly mesenchymal stem cells (MSCs) for knee osteoarthritis (KOA) and cartilage injury reveals significant functional improvements in patients, with no severe adverse effects. The study found better outcomes with multiple injections compared to a single dose. Despite mixed radiological results, Wharton’s jelly MSCs show potential as a cornerstone for future KOA treatments. The follow-up period ranged from 3 to 48 months, emphasizing the long-term benefits of this promising therapy. Read more: https://lnkd.in/dYQ-9tDs

A big thank you to the American University of Ras Al Khaimah for inviting CellSave to conduct an educational workshop for biotechnology students! It was a pleasure engaging with the bright minds of tomorrow, sharing insights into stem cell science and the latest advancements in regenerative medicine. A special appreciation to Professor Rawad Hodeify, Department Chair & Associate Professor – Medical Biotechnology, for facilitating this opportunity and fostering a learning environment that bridges academia and real-world innovation. At CellSave, we are committed to raising awareness about the potential of stem cell banking and regenerative therapies, and we look forward to more collaborations that inspire the next generation of scientists. #CellSave #StemCellScience #RegenerativeMedicine #Biotechnology

Mesenchymal stem cell (MSC) therapy has already proven its safety, and now, new advancements are bringing us closer to maximizing its effectiveness! Lu and Allickson (2025) emphasize that the key to optimizing MSC therapy lies in standardization, personalized patient selection, and cutting-edge gene editing technologies like CRISPR-Cas9. These innovations are revolutionizing the field, making MSC therapy more effective across various applications, from regenerative medicine to immunotherapy. The future of MSC therapy is brighter than ever—paving the way for transformative treatments that could change countless lives. 💙✨ Read more: https://lnkd.in/d5mW8yps. #Healthcare #mesenchymalstemcells #stemcelltherapy #recentresearch

في مقابلة حصرية مع سارة الحاج علي، الرئيس التنفيذي لشركة سيل سيف أرابيا، تتحدث عن ريادة الشركة في مجال حفظ الخلايا الجذعية والطب التجديدي وتأثير ذلك على صحة المرأة. منذ تأسيسها في 2005، أصبحت سيل سيف أرابيا رائدة في تقديم حلول مبتكرة لعلاج العديد من القضايا الصحية التي تؤثر على النساء، مثل العقم، الأمراض المزمنة، وعلاج السرطان. من خلال تخزين أكثر من 750,000 وحدة من الخلايا الجذعية، تضمن الشركة أن يكون لها دور محوري في تحسين صحة المرأة اليوم وفي المستقبل. كما تستعرض سارة الحاج علي التطورات الجديدة في الطب التجديدي وكيف يمكن لهذه التكنولوجيا أن تحدث ثورة في علاج الأمراض الصحية الأكثر تحديًا التي تواجه النساء. Sarah Al-Hajali اقرأ المزيد: https://lnkd.in/dajKKxuM

A recent phase 3 clinical trial in China by Yu et al. (2025) compared two stem cell transplantation approaches for patients with haematological malignancies: haploidentical peripheral blood stem cells (PBSCs) plus unrelated cord blood, and haploidentical PBSCs plus bone marrow. The study found that the combination of haploidentical PBSCs and unrelated cord blood resulted in a significantly higher 1-year disease-free survival rate of 82.2% compared to 65.6% for the bone marrow group. This approach also showed a more favorable safety profile, with fewer transplantation-related deaths and lower rates of severe infections. The results suggest that this combination could be a superior treatment option for this patient group. Read more: https://lnkd.in/dHGpkQbp #healthcare #recentresearch #umbilicalcord #bloodtumor #cancerresearch

A 5-year follow-up study by Chin et al. (2025) on Cytopeutics® CLV-100, an umbilical cord-derived mesenchymal stem cell (UC-MSC) infusion, confirms its long-term safety and immunomodulatory effects. Eleven healthy volunteers who received a single infusion (low or high dose) showed no adverse effects, stable cancer marker levels, and healthy organ function, even in subjects over 60. The anti-inflammatory benefits were more pronounced in the high-dose group, suggesting potential protection against age-related frailty and inflammation-related diseases. Read more: https://lnkd.in/dQq6prgK #stemcelltherapy #recentrecsearch #umbilicalcordstemcells #MCSs #healthcare